規制動向
2026年8月26日•1分で読めます
FDA Approves ANDA078101 for Teva’s Levetiracetam Oral Tablets
The FDA has approved labeling submissions for Teva Pharm’s discontinued levetiracetam tablets (250 mg, 500 mg, 750 mg, 1 g) under ANDA078101.
規制動向
2026年8月23日•1分で読めます
Teva UK reports labeling error on Ponlimsi (Denosumab) 60mg carton
Teva UK Limited has identified a labeling mistake on the Ponlimsi (Denosumab) 60 mg pre‑filled syringe carton, which incorrectly states “For application to the skin” despite the product being licensed for subcutaneous injection.
1